New diabetes shot shows promise in Late-Stage trial
NCT ID NCT06777238
First seen Dec 16, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This Phase 3 study tests an injectable drug called GZR18 in 274 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants receive either GZR18 or a placebo to see if the drug improves blood sugar levels, weight, and waist size. The trial is active but not recruiting, and results will help determine if GZR18 is a safe and effective treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing
Beijing, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GZR18 injection
What this could lead to
If successful, this could offer a new injectable option to help people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong
This is a Phase 3 trial, but results may not apply to all populations. Side effects are possible, and the drug may not prove significantly better than placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.